



Marcin Wlodarski, MD, PhD

Associate Professor /Faculty Member., Department of Hematology
Director, Bone Marrow Failure Program

Attending, Clinical Hematology

St. Jude Children's Research Hospital

262 Danny Thomas Place | Mail Stop 341 | Memphis, TN 38105

marcin.wlodarski@stjude.org | t: (901) 595-2484 | f: (901) 595-2176

Assistant: lisa.dubeck@stjude.org t: (901) 595-1750

www.stjude.org/research/labs/wlodarski-lab.html

Bio Short:

Physician-scientist specializing in bone marrow failure (BMF) and pediatric myelodysplastic syndromes (MDS). He is Associate Professor and Director of the Bone Marrow Failure Program at St Jude Children's Hospital. Dr. Wlodarski's lab focuses on genetics of BMF/MDS predisposition syndromes (including SAMD9/SAMD9L and GATA2 syndromes) and somatic genetic rescue and clonal evolution in BMF/MDS. Education: Medical school in Berlin, Germany and Karolinska Institute Stockholm; MD/PhD (2009) from Charité Medical School, Humboldt University Berlin, and Dr. honoris causa from Semmelweis University (2025). Residency in Pediatrics and Adolescent Medicine (2014), and Fellowship in Pediatric Hematology/Oncology (2017), both from University of Freiburg, Germany.

Bio Long:

Dr. Marcin Wlodarski is an Associate Professor at St. Jude Children's Research Hospital, where he directs the Bone Marrow Failure (BMF) and Myelodysplastic Syndromes (MDS) Program. He received his MD and PhD from Charité Medical School, University of Humboldt, Berlin, with additional training at Karolinska Institute, Stockholm. His postgraduate training included residency in pediatrics and adolescent medicine and hematology/oncology fellowship at the University of Freiburg.

Dr. Wlodarski's research focuses on elucidating the genomics of inherited hematological disorders predisposing to BMF, MDS, and leukemia. His laboratory has made pivotal discoveries in genetic syndromes caused by mutations in SAMD9/SAMD9L, GATA2, RPA1, and MDM4, revealing novel disease mechanisms such as somatic genetic rescue and clonal evolution in pediatric BMF/MDS. He integrates advanced genomic techniques with patient-derived models to bridge basic science and clinical application.

At St. Jude, Dr. Wlodarski established a comprehensive BMF/MDS program, implementing standardized care pathways and a consultation service for affiliate clinics. He is involved in clinical trials for patients with BMF, including a Phase 2 study of CPX-351 for secondary myeloid malignancies. His efforts are divided between clinical practice (30%) and research (70%), leading a team of six MD- and PhD-level researchers who work on translational projects. Dr. Wlodarski has published over 100 peer-reviewed articles, including papers in high-impact journals like Nature Medicine, Blood, and Lancet Haematology. His work has been recognized with several awards, including the Humboldt Prize for Best Doctoral Thesis, the Tito Bastianello Young Investigator Award, the Kind-Philipp Prize, and Dr. honoris causa from Semmelweis University. He chairs the US-wide registry for pediatric BMF/MDS of the Northern American Aplastic Anemia Consortium and was chair of BMF Scientific Committee of the American Society of Hematology. Additionally, he serves on ClinGen Expert panels. His research is supported by competitive grants, and he actively mentors early-career scientists, with multiple securing prestigious NIH career development awards